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Methotrexate was developed in 1949 as a synthetic folic acid analogue to compete with folic acid and thus interfere with cell
replication. While initially developed as a potential treatment for acute lymphoblastic leukaemia, a serendipitous observation
led to methotrexate’s use to eﬀect the dramatic cure of a case of advanced choriocarcinoma. This prompted the exploration for
the potential of methotrexate to treat other conditions involving disordered trophoblastic tissue. Methotrexate has subsequently
revolutionized the treatment of two pregnancy-related conditions—gestational trophoblastic neoplasia and ectopic pregnancy.
This article reviews the development of modern treatment protocols that use methotrexate to medically treat these two important
gynaecological conditions.
1.Introduction
Methotrexateisanantifolatedrugwhichinhibitscelldivision
by interfering with DNA replication [1]. It is used clinically
in medicine to treat a range of cancerous and noncancerous
conditions. Methotrexate is currently used in gynaecology
to treat disorders arising from trophoblastic tissue, namely,
ectopic pregnancy and gestational trophoblastic disease.
Whilst the incidences of these conditions in pregnancy are
relatively rare (ranging from 0.7% for GTD [2] to 1-2%
for ectopic pregnancy [3]), their impact on the lives of
youngwomenofreproductiveage,bothintermsofmortality
and morbidity (especially loss of reproductive potential),
are signiﬁcant. Methotrexate has contributed to alleviating
some of the disease burden of ectopic pregnancy, where
it aﬀords approximately 25% of women a nonsurgical and
fertility-preserving treatment option [4]. Methotrexate has
dramatically improved survival outcomes in gestational tro-
phoblastic neoplasia, where surgery is now only occasionally
used as an adjunct to treatment [5].
This article reviews methotrexate and its mechanism
of action, gestational trophoblastic neoplasia and ectopic
pregnancy, and how modern treatment protocols using
methotrexate to medically treat these two conditions devel-
oped.
2.Methotrexate
2.1. History and Origins. Methotrexate was one of the ﬁrst
drugssynthesizedforaspeciﬁcchemotherapeuticpurpose—
in situ folic acid inhibition for the treatment of acute
lymphoblastic leukaemia (ALL) in children [1]. Its history
is closely related to the discovery and characterisation of
folic acid [6]. The “factor” later shown to be folic acid was
discovered by missionary physician Lucy Wills in India in
the 1930s, when she used Marmite to treat megaloblastic
anaemia in impoverished, pregnant textile workers [7]. In
the 1940s, this “factor” was isolated from spinach leaves
and called folic acid (folium being Latin for leaf) [7]. At
this time, American pathologist/pediatrician Sidney Farber
had noted the morphological similarities between ALL and
megaloblasticanaemiaandtrialledfolicacidinthetreatment
of children with ALL; however, it paradoxically accelerated2 ISRN Obstetrics and Gynecology
disease progression [1]. Folic acid-deﬁcient diets were sub-
sequently shown to decrease the leukaemia cell count, and
this led to the development of folic acid antagonists [1].
Methotrexate was the second drug to be developed for this
purpose by a group of researchers at the Lederle Laboratories
in 1949 [1, 7]. Methotrexate induced remission of ALL in
children but did not cure the disease [6]. Its application to
the treatment of a woman with terminal choriocarcinoma
in 1956 produced the ﬁrst cure of a solid tumour by chem-
otherapy[6],anditsuseinthetreatmentofGTNandectopic
pregnancy expanded from there [8].
2.2. Mechanism of Action. Methotrexate was created to com-
pete with folic acid for biological activity in the body. It does
so by competitively binding with the enzyme dihydrofolate
reductase with much greater aﬃnity than folic acid [9]. This
prevents the conversion of dihydrofolate to tetrahydrofolate,
which is essential in the de novo synthesis of purine
nucleotides and thymidylate, which are themselves essential
substrates of DNA synthesis, repair, and cell proliferation
[1, 10]( Figure 1). Methotrexate thus blocks cell proliferation
in the S phase of the cell cycle during which DNA replication
occurs, making rapidly dividing cells such as trophoblast
especially susceptible to its action [1, 10]. It also means that
methotrexate has a nonspeciﬁc mechanism of action, and
with this comes the potential for numerous side eﬀects.
2.3. Clinical Use and Side Eﬀects. Methotrexate has a wide
range of indications that extend beyond its original design
for the treatment of hematological malignancy. It is still
used for the treatment of neoplasms such as leukaemias and
lymphomas, but also lung cancers, breast cancer, head and
neck cancers, osteosarcomas, bladder cancer, and GTN [1,
11]. It has been found to have an immunomodulatory eﬀect
in autoimmune conditions such as rheumatoid arthritis,
although its mechanism of action here remains unknown,
and psoriasis, where it is thought to impede the rapid
turnover of skin cells characteristic of the condition [1, 11],
andisusedoccasionallyinCrohn’sdisease,multiplesclerosis,
and psoriatic arthritis [11]. It is also used in the treatment of
ectopic pregnancies by extension of its use in GTN [8, 11].
Owing to its nonspeciﬁc actions on cell division,
methotrexate is associated with toxicities and side eﬀects that
include every organ system [11]. The exact likelihood and
incidences vary slightly depending on the condition being
treated, the route of administration, the dosage, and length
of treatment [11]. By its mechanism of action methotrexate
preferentially targets rapidly dividing cells; therefore, the
hematological, gastrointestinal, and dermatological systems
which feature a high turnover of cells are the most likely to
display signs and symptoms of toxicity such as neutrope-
nia and generalized myelosuppression, nausea, vomiting,
diarrhoea, and gastrointestinal inﬂammation as well as
generalized erythema, rash, photosensitivity, and alopecia
[11] .T h e s es i d ee ﬀects have been greatly ameliorated in the
ﬁeld of gynaecology by the development of a low, single-
dose protocol in the treatment of ectopic pregnancies [12],
and to some extent with the use of folinic acid (a form
of tetrahydrofolate) rescue in GTN chemotherapy protocols
[8, 11, 13].
3.GestationalTrophoblastic Neoplasia
3.1.HistoryandDeﬁnition. Gestationaltrophoblasticdisease
(GTD) consists of a range of premalignant and malignant
tissues that arise from trophoblastic cells in association with
any type of gestational event. The premalignant forms of
the disease are called molar pregnancies and comprise over
90% of GTD [14]. Molar pregnancies consist of abnormally
proliferativetrophoblastictissueandoccurafteranabnormal
fertilization event. There are two types of molar pregnancies:
complete hydatidiform mole (CHM), where there is no
maternal chromosomal material in the ovum and either one
sperm fertilizes the ovum and replicates its DNA (androge-
netic monospermic-90%) or two sperm fertilize the empty
ovum (androgenetic dispermic-10%), and partial hydatidi-
form mole (PHM) where an apparently normal ovum with
maternal chromosomal material is fertilized by two sperm
resulting in triple the normal amount of chromosomal
material (biparental triploid) [5]. A rare form of biparental
CHM is associated with an autosomal recessive mutation on
chromosome 19q (NLRP7) and is thought responsible for
recurrent molar pregnancy [5]. Malignant forms of GTD
mainly consist of invasive mole and choriocarcinoma, and
occasionally the rare placental-site trophoblastic tumour
(PSTT).ThesemalignantformsofGTDarecalledgestational
trophoblastic neoplasias (GTN).
Hippocrates himself was most likely referring to GTD
when he described “dropsy” of the uterus around 400BC [5].
It wasn’t until 1895 that an association between pregnancy
and GTD was conﬁrmed when Marchand determined that
the tumours arose from fetal cell lines [5, 15]. Prior to
the 1950s and the era of chemotherapy, choriocarcinoma,
the most aggressive form of GTN, was fatal in 90–95%
of cases where metastases were present [15]. In 1956, the
antifolate drug methotrexate (see above) was given to a
young woman with advanced metastatic choriocarcinoma
who was expected to die within a matter of months. The idea
to test methotrexate for this condition came from an earlier
observation where methotrexate given to a patient with
malignant melanoma unexpectedly eradicated the presence
of βhCG from her urine [6]. This terminally ill woman
with choriocarcinoma not only got better with methotrexate
treatment but was discharged home four months later with
no identiﬁable disease [6]. This was the ﬁrst cure of any solid
tumour with chemotherapy [6].
3.2. Incidence, Risk Factors, and Mortality. The incidence of
molar pregnancies is notoriously diﬃcult to determine, as
the diagnosis relies on highly specialized histopathological
examination[16].Furthermore,estimatesoftheincidenceof
molar pregnancies are calculated against either total number
of pregnancies, deliveries, or both, creating confusion, and
these statistics themselves are prone to underreporting [16].
EstimatesoftheincidenceofmolarpregnancyintheWestern
world including Australia are 0.5–1/1000 pregnancies, whilstISRN Obstetrics and Gynecology 3
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Figure 1: The mechanism by which methotrexate inhibits cellular proliferation. Active transporter includes the reduced folate carrier and
an endocytic pathway activated by a folate receptor; dUMP: deoxyuridine monophosphate; CH2FH4: methylenetetrahydrofolate.
the much higher incidence in Asia (1-2/1000 pregnancies
in Japan and China and up to 12/1000 pregnancies in
Indonesia) is believed to be genuinely reﬂective [16].
Extremes of maternal age and previous molar pregnancy
are the two most strongly proven risk factors [14]. Preg-
nancies occurring during teenage years carry a 1.5–2-fold
increased risk of molar pregnancy, whereas, in pregnancies
occurring when a woman is 40-year old or more, the risk is
increased 5–7.5-fold [5, 16]. Similarly, if a woman has had
one previous molar pregnancy, her risk of recurrence in a
future pregnancy is 1% compared to 0.1% of the general
population, and if she has had two or more, this risk rises
to between 16 and 28% [14, 16]. Recurrent disease may be
duetotheaforementionedgeneticmutation(NLRP7).Other
risk factors such as maternal blood group, smoking, parity,
and oral contraceptive pill use have not been consistently
proven [14]; however, the worldwide distribution of areas
with high levels of vitamin A (beta carotene) deﬁciency,
which causes abnormal spermatogenesis and spontaneous
abortion in Rhesus monkeys, correlates with areas with a
high incidence of molar pregnancy [5, 14].
Molar pregnancies have malignant potential, with local
invasion a feature in 15% of cases and/or metastases in
4% [17]. Complete moles have a higher rate of persistence
and neoplastic potential at 6–30% of cases, compared to
0.5–3% after partial mole [5, 14, 18]. Risk factors for
developing invasive, persistent disease are: serum βhCG
levels >100,000IU/L at diagnosis, associated large ovarian
theca lutein cysts (>6cm), uterine size larger than expected
for dates, and maternal age >35y.o. [19]. Choriocarcinoma
and PSTT, the other forms of GTN, occur more frequently
after nonmolar pregnancies at a rate of between 1:20,000
and 50,000 pregnancies [5, 20]. Approximately 25% of cases,
however, still occur after complete molar pregnancy [20],
and molar pregnancies precede 90% of cases of GTN [14].
The advent of chemotherapy changed metastatic GTN
from a fatal disease in 90–95% of cases [15] to being curable
in 85% of cases [5, 20]. For women with low-risk (see below)
GTN, the cure rate approaches 100% [20]. However, despite
a good 5-year-survival rate of 89.5% [21], there is scope for
further improvement in the management of GTN. Mortality
from choriocarcinoma after nonmolar pregnancy is 21%
compared to 6% after molar pregnancy and is mainly due
to late diagnosis when the disease is already advanced [22].
Deaths still occur from drug resistant disease. Cost-eﬀective
screening or surveillance measures to identify women with
GTN after nonmolar pregnancies would potentially help to
further improve survival by diagnosing the condition earlier
in this cohort. Newer agents with greater eﬃcacy and lesser
toxicity could greatly improve the care of women with this
condition [5, 22].
3.3. Management of Molar Pregnancy. First-line treatment
for molar pregnancies is suction curettage, and indeed the
majority of molar pregnancies are diagnosed after histo-
pathology testing of products of conception from this
procedure [23]. This is because GTD presents similarly
to and is frequently misdiagnosed as incomplete/missed
miscarriages, and even ectopic pregnancy. Once the products
of conception have been removed surgically and the patho-
logical diagnosis conﬁrmed as either complete or partial
molar pregnancy, patients are followed up with serial serum
and/or urinary βhCG levels until they normalize (<5IU/L)
[24, 25]. 98% of women who develop GTN (invasive mole)
will be identiﬁed this way within the ﬁrst 6 months after
surgical evacuation [26]. Serum/urinary βhCG levels should
be measured at least every 2 weeks [5, 20], and women
whose βhCG normalizes within 56 days have a reduced
risk of developing GTN [5] .T h e ya r ef o l l o w e du pf o ra
further 6 months, and if their βhCG levels remain normal,4 ISRN Obstetrics and Gynecology
Table 1: Modiﬁed WHO prognostic scoring system as adapted by FIGO [30].
S c o r e s 01 24
Age <40 >40 — —
Antecedent pregnancy Mole Miscarriage Term —
Interval months from index pregnancy <4 4–6 7–12 >12
Pretreatment serum βhCG (IU/L) <103 103–104 104–105 >105
Largest tumour size (including uterus) (cm) <33 - 4 ≥5—
Site of metastases Lung Spleen/kidney Gastrointestinal Liver/brain
Number of metastases — 1–4 5–8 >8
Previous failed chemotherapy — — Single drug ≥2d r u g s
Table 2: GTN FIGO staging and classiﬁcation [30].
Stage I Disease conﬁned to the uterus
Stage II GTN extends outside of the uterus but is limited to
genital structures (adnexa, vagina, broad ligament)
Stage III GTN extends to the lungs, without genital tract
involvement
Stage IV All other metastatic sites
they are then discharged from surveillance. Of the women
whose βhCG took longer than 56 days to normalize, a
study by Sebire et al. showed that extended surveillance
for 2 years picked up only 1 additional woman who went
on to develop GTN and required treatment. Hence since
2007, women whose βhCG takes longer than 56 days to
normalize are followed up for 6 months from the time
of βhCG normalization [26]. A total of 3 of 6701 women
(<0.05%) who went on to develop GTN were missed
by this surveillance protocol and represented with clinical
symptoms [26].
3.4.ManagementofGTN. IfhCGfollowupforGTDdetectsa
persistence or rise in levels, invasive and therefore malignant
forms of GTD, called gestational trophoblastic neoplasias
(GTN), are assumed [27]. The Federation of Gynaecolo-
gists and Obstetricians proposed the following consensus
diagnostic criteria of GTN using βhCG surveillance: (1) a
βhCG level plateau of four values ±10% over 3 weeks, (2) a
βhCG level increase of more than 10% of three values over
2 weeks, and (3) persistence of detectable βhCG for more
than 6 months after curettage [20]. GTN can, however, occur
after any form of pregnancy; approximately 50% follow
a normal pregnancy, 25% after molar pregnancy, and the
remaining 25% after other gestational events such as ectopic
pregnancies and miscarriages [20]. Those occurring after a
nonmolar pregnancy generally present later and with more
advanced disease as they are not identiﬁed through βhCG
surveillancebutthroughclinicalpresentationandoftencarry
a worse prognosis as a result [22].
Repeat suction curettage is generally avoided. It carries
high risk of uterine perforation and in particular, signiﬁcant
haemorrhage, as trophoblastic tissue is highly vascular and
prone to arteriovenous malformations in GTN [28]. More
than 50% of GTN patients will still need chemotherapy after
a repeat curettage; therefore, chemotherapy is the preferred
ﬁrst-line treatment [5]. For women who have completed
their families, hysterectomy is an option to treat GTN
apparently conﬁned to the uterus; however, because of GTNs
ability to micrometastasise very early, this does not obviate
the need for βhCG surveillance or the possibility of requiring
chemotherapy [5].
The form of chemotherapy (single agent versus multiple
agents) is determined by the Modiﬁed WHO Prognostic
Index Score (PIS) of the patient [5, 20]( Table 1). Unlike
other cancers where the staging (i.e., anatomical spread)
of the tumour best determines management and correlates
to prognosis, it is the presence of certain risk factors that
has been shown to correlate most highly with treatment
outcome and prognosis in GTN [29]. Low-risk assessment
indicates that the patient is likely to respond favourably to
single-agent chemotherapy, and high-risk patients require
moreaggressive,multiagentchemotherapytoachievedisease
remission [29]. The FIGO staging of GTN is still used to
describe anatomical spread of the disease [29]( Table 2).
Low-risk disease is deﬁned as a PIS of 0–6 and represents
approximately 95% of GTN patients [5]. These women are
highly likely to respond to single-agent chemotherapy with
either methotrexate or actinomycin D (a very old antibi-
otic with anticancer activity through inhibition of DNA
replication), the two most widely used ﬁrst-line agents
[31]. Various methotrexate regimens are used, with little
evidence of the superiority of one regimen over the other
[29]. The remission rate of methotrexate therapy ranges
from 50 to 90% depending on the route, dose, frequency
of administration, and patient selection criteria used [5].
Some studies suggest that actinomycin D is more likely to
induce remission than methotrexate [5]; however, it also
seems more likely to cause toxicity such as alopecia [5, 29].
An 8-day multidose methotrexate protocol with intervening
folinic acid (to minimize toxicity) was ﬁrst suggested by
Bagshawe and Wilde in 1964 [32], and this regimen is the
ﬁrst-line treatment for low-risk disease used by large centres
for trophoblastic disease management and research in both
the US and the UK, and hence the most widely used regimen
in the world [5, 31, 33]. It achieves remission in 90% of low-
risk stage I patients and 70% of low-risk stage II-III patients
[29] and is associated with low toxicity—<15% patients
experience nausea, <5% vomiting, and approximately 2%
develop mouth ulcers, sore eyes or chest or abdominalISRN Obstetrics and Gynecology 5
pain from pleuritic or peritoneal serositis [5, 29]. If ﬁrst-
line treatment fails, treatment with the alternate ﬁrst-line
agent (methotrexate or actinomycin D) or even multiagent
chemotherapy are used to attain an overall survival rate of
nearly 100% [5]. Treatment is continued until the serum
βhCG normalizes (<5IU/L) for at least three consecutive
weeks [31].
Multiagent chemotherapy is used to treat high-risk GTN,
deﬁned as stage IV disease or stage II-III disease with
a PIS of 7 or above, as well as PSTT and treatment-
refractive low-risk disease [29]. Again, a wide variety of reg-
imens are employed worldwide, with very little evidence to
show superiority of any one regimen. The most widely used
multiagent chemotherapy regimen EMA-CO-consists of:
etoposide, methotrexate, actinomycin D, cyclophosphamide,
and vincristine (Oncovin). It achieves a 5-year-survival rate
of 86.5% [29, 34] and is a relatively well-tolerated regimen,
with alopecia being the commonest side-eﬀect, high-grade
haematologic toxicities experienced by less than 2% of
patients, and more than half of patients retaining their fer-
tility [29]. There are no randomized controlled clinical trials
comparing EMA-CO to other combination chemotherapies
[34]. Other combination therapies include EMA (etoposide,
methotrexate, and actinomycin D) with one retrospective
study suggesting similar eﬃcacy but inconclusively less
toxicity compared to EMA-CO, and MAC (methotrexate,
actinomycin D, and chlorambucil) which in a retrospective
study has much lower durable remission rates compared to
EMA-CO and requires a greater number of cycles to achieve
remission [29].
Methotrexate has revolutionized the treatment of GTN.
Prior to 1956, women with what we now call low-risk
disease would have frequently lost their fertility through
hysterectomy, which was the mainstay of treatment. Those
with high-risk disease inevitably died from the condition.
Methotrexate not only replaced surgery as a treatment
option, to this day it is used to cure almost 100% of women
withlow-riskdiseaseandupto86%ofwomenwithhigh-risk
disease in combination with newer chemotherapeutics.
4.Ectopic Pregnancy
4.1. Deﬁnition and History. An ectopic pregnancy is one
that implants outside of the uterus, in one of the Fallopian
tubes in 95.5% of cases [35], but potentially anywhere in the
abdominal and pelvic cavities. The name is derived from the
Greek word ektopos, meaning “out of place” [36], and the
condition has been described in medical literature since the
11th century when the Arabic physician Abulcasis extracted
a fetus from a swelling he drained through the abdominal
wall [37]. It was considered a “universally fatal accident”
until the 19th century, when attempts such as “vaginal
section,” maternal starvation, purging, bleeding, strychnine
administration,andfetalmorphineinjection“improved”the
survival prognosis to between 72 and 99% [37].
4.2. Signiﬁcance, Risk Factors, Incidence, and Mortality. The
incidence of ectopic pregnancies is between 1-2% of all
pregnancies[3,38].Recognizedriskfactorsfallintotwocate-
gories:contraceptivefailure,whereanintrauterinedevicehas
not prevented fertilisation and is associated with a 3-4% risk
of ectopic pregnancy [39], and reproductive failure, where
risk factors include a history of pelvic inﬂammatory disease
(especially Chlamydia trachomatis [40]), tubal damage from
o t h e rc a u s e ss u c ha sp r e v i o u ss u r g e r y ,p r e v i o u se c t o p i c
pregnancies, smoking, advancing maternal age, infertility,
and assisted reproductive techniques [41, 42].
Ectopic pregnancy is still a potentially life-threatening
condition, as the invasive and angiogenic nature of tro-
phoblastic tissue outside of the specialized lining of the
uterus means that the growing pregnancy can disrupt
maternal vasculature and cause fatal haemorrhage. The
advent of modern surgical techniques, anaesthesia, blood
transfusions, and antibiotics in the early 20th century, and
more recently ultrasound and medical treatment for the
condition in the late 20th century, have seen the mortality
of ectopic pregnancy fall to 0.5 deaths per 100,000 live births
in the US, 0.47 per 100,000 maternities in the UK, and 0.13
per 100,000 births in Australia [38, 43, 44].
4.3.SurgicalManagement. Ectopicpregnancieswereincreas-
ingly described in 17th and 18th century France, either at
autopsy or during abdominal surgeries [37, 45]. In America,
the ﬁrst abdominal surgery for ectopic pregnancy was
performed in 1759 by John Bard, and surgical management
became increasingly attempted in the 19th century [45]. The
survival rate of women who were operated on in the 1800s,
however,was5in30,worsethanthe1in3whosurvivedwith
no intervention [45]. Robert LawsonTait, an eminent British
surgeon, described treatment of ruptured ectopic pregnancy
by ligating bleeding vessels at laparotomy in 1884. This was a
major advance in developing eﬀective surgical management
of this condition [45].
As operative techniques have developed and improved,
laparoscopy has replaced laparotomy as the preferred
approach, mainly due to the signiﬁcant cost savings it
confers. This is a result of shorter operating time, less
intraoperative blood loss, shorter hospital stay and shorter
convalescence associated with laparoscopy as opposed to
laparotomy[46].Thesefactorsmakelaparoscopymuchmore
acceptable to patients as well. However, systematic review
suggests that the laparoscopic approach is signiﬁcantly less
successful than laparotomy in eliminating ectopic pregnancy
(OR 0.28, 95% CI 0.09–0.86), mainly due to a higher inci-
dence of persistent trophoblastic tissue after salpingostomy
(OR 3.5, 95% CI 1.1–11) [47].
Two techniques are described to remove the ectopic
pregnancy from the Fallopian tube salpingectomy,w h e r e
the pregnancy is removed en bloc with the tube and
salpingostomy, where an incision is made on the Fallopian
tube over the swelling, the ectopic pregnancy carefully
removed with forceps or irrigation and the incision either
closed or left to heal by secondary intention [45]. There
are no prospective studies comparing subsequent fertility
rates after either salpingectomy or salpingostomy, however,
retrospective studies suggest no signiﬁcant diﬀerence [48].6 ISRN Obstetrics and Gynecology
Salpingostomy is, however, associated with a 5–8% risk of
persistent trophoblastic tissue and is less cost eﬀective as
a result of the subsequent monitoring and treatment that
this necessitates [48]. Salpingectomy is considered preferable
when there is signiﬁcant haemorrhage and/or damage to
the tube, when ectopic pregnancy has recurred in the same
Fallopian tube and when future pregnancies are not desired
[45]. A prospective, randomized control trial is currently
underway to evaluate whether one technique is better than
the other in the management of women with ectopic preg-
nancies and healthy contralateral tubes who wish to conceive
in future [49]. In the meantime, preference is largely region
and operator dependent.
4.4. Medical Management. Extirpative surgery remained the
only eﬀective medical intervention for ectopic pregnancy
until medical management was (re-)introduced in the 1980s
[8]. Methotrexate was ﬁrst used in diagnosed ectopic preg-
nancies in the 1960s to aide safe surgical removal of the
placenta from its abdominal implantation sites in second-
and third-trimester cases [50]. In the 1980s, the use of
methotrexate for treatment of ectopic pregnancies was based
on its use in GTN, that is, ﬁxed, multidose regimens with
intervening folinic acid rescue [13, 51]. These were full
chemotherapeuticdoses,whichalthoughachievingcure,also
produced signiﬁcant side eﬀects in women. The potential of
methotrexate/folinic acid therapy as an outpatient treatment
for ectopic pregnancy was ﬁrst explored by Stovall et al.
in 1989 [12]. At this time, however, the gold standard of
diagnosis of ectopic pregnancy was by direct visualization
at surgery, as ultrasound was still too crude an instrument
to rely upon in this potentially life-threatening situation
[52]. Surgery as part of the diagnostic logarithm of ectopic
pregnancy heavily negated the beneﬁts of then proceeding to
medical management, both in terms of cost eﬀectiveness and
acceptability to patients [8, 46].
Transvaginal ultrasonography (TVUS) became increas-
ingly available in the late 1980s, and by the mid 1990s
sensitivity and speciﬁcity were calculated at 84.4 and 98.9%,
respectively, [53]. This rapid technological advancement and
improvement in image quality meant that, by the mid to
late 1990s, TVUS became the preferred means of diagnos-
ing ectopic pregnancy although laparoscopic visualization
remains the gold standard for diagnosis [52].
Stovall et al. remained the pioneers of outpatient treat-
ment of ectopic pregnancies with methotrexate and under-
tookmuchoftheresearchthatunderpinsthecurrent“single-
dose” regimen and monitoring protocol used worldwide
today [54]. Their ﬁrst trial with the aim of using a single dose
of methotrexate to treat ectopic pregnancy was published
in 1991, with a cure rate of 96.7% [55]. They included
TVUS in a nonsurgical workup logarithm of patients with
suspected ectopic pregnancies from 1993 [56] and developed
a monitoring protocol which is based on serial serum βhCGs
taken on day 1, 4, 7, and weekly until resolution. Eﬃcacy of
treatment is determined when there is a ≥15% fall in serum
βhCG between day 4 and day 7. This deﬁnition of treatment
success has a positive predictive value (PPV) of 93%, with
a sensitivity of 93% and a speciﬁcity of 84.2% [57]. If there is
not a ≥15% fall in serum βhCG between day 4 and day 7, a
second (and third) intramuscular injection of methotrexate
(50mg/m2)canbegiven.Approximately20%ofpatientswill
requiremorethanonedoseofmethotrexatetoachieveβhCG
normalization [54].
The use of methotrexate in the treatment of ectopic
pregnancy is limited by its eﬃcacy, which drops sharply from
96% at βhCG serum levels between 2000 and 4999IU/L, to
86% for serum βhCG levels between 5000 and 9999IU/L
(OR 3.76, 95% CI 1.16–12.33)[58]. This necessarily limits
the number of women with ectopic pregnancies eligible for
medical management at the time of diagnosis.
Methotrexate has been combined with mifepristone
(RU486), a progesterone antagonist, in the treatment of
stableectopicpregnancies.Twotrialshaveshownthatsingle-
dose methotrexate was slightly less successful at curing ec-
topic pregnancy than when 600mcg of mifepristone was
added orally (OR 0.84, 95% CI 0.71–1.0) [59]. In addition
to the borderline signiﬁcance, van Mello notes that the
cohorts of women featured relatively low starting serum
βhCGs (between 346 and 1,679IU/L), βhCG itself being the
strongest prognostic indicator of medical treatment success
[59, 60].
Other medical treatments such as prostaglandins and/or
hyperosmolar glucose have been compared to treatment
with systemic methotrexate. Prostaglandins alone or in
combination with hyperosmolar glucose showed no dif-
ference in treatment success or side eﬀects compared to
methotrexate alone, and a study examining methotrexate
versus hyperosmolar glucose was abandoned due to a high
failure rate in the latter group (OR 0.30, 95% CI 0.05–
2.0) [47]. Alternative means of administering methotrexate
have also been studied, for example direct injection into the
tubalmassatlaparoscopyorwithultrasoundguidancetrans-
vaginally. Both methods require clinicians with a higher
skill set than that required for systemic administration of
methotrexate and are less successful treatments than laparo-
scopic salpingectomy [47]. Hence, systemic methotrexate,
particularly the “single-dose” regimen, remains the only
medical treatment of ectopic pregnancy in common clinical
use.
Most centres use a protocol to carefully select which
women diagnosed with ectopic pregnancies are suitable
for medical outpatient treatment with “single-dose” sys-
temic methotrexate. This is determined primarily by the
haemodynamically stable condition of the woman and lack
of clinical evidence of ectopic pregnancy rupture: blood
pressure, pulse rate and oxygen saturation within normal
limits, no evidence of guarding or rigidity on abdominal
examination, normal red blood cell indices on blood tests,
and minimal or no evidence of blood in the Pouch of
Douglas on TVUS. Additionally, determinants of likelihood
of medical treatment success are assessed when deciding on
whether a woman is suitable for medical treatment of her
ectopic pregnancy. They generally include: a serum βhCG
with an upper limit between 3000–5000IU/L, a gestational
sac size of less than 3-4cm, and no fetal heart visualized on
TVUS.ISRN Obstetrics and Gynecology 7
4.5. Surgery versus Medical Treatment. Systemic methotrex-
ate has been compared to laparoscopic salpingostomy as a
treatmentfortubalectopicpregnancy.Multidosemethotrex-
ate was comparable to laparoscopic salpingostomy in terms
of treatment success in women with ectopic pregnancies of
any size or starting serum βhCG level (OR 1.8, 95% CI 0.73–
4.6);however,itwasassociatedwithsigniﬁcantlygreaterinci-
dence of side eﬀects (60% versus 12%) and poorer health-
related quality of life (P<0.05) [47]. Multidose methotrex-
ate was also a more expensive treatment option [47]. Single-
dose systemic methotrexate compared to laparoscopic salp-
ingostomy in women with selected ectopic pregnancies (less
than4cmonTVUSandwithstarting serum βhCGslessthan
10,000IU/L) was a far less eﬀective treatment for ectopic
pregnancy (OR 0.38, 95% CI 0.20–0.71), however, when
allowing for additional doses of methotrexate if serum βhCG
was falling inadequately, there was no diﬀerence in treatment
success compared with laparoscopic salpingostomy (OR 1.1,
95% CI 0.52–2.3) [47].
Methotrexate therefore has an established and well-
proven role in the treatment of ectopic pregnancy, and
althoughitsuseislimitedbyserumβhCGlevelandtoalesser
extent, ectopic pregnancy size, it nevertheless confers cost,
fertility, and arguably improved treatment-related quality of
life and recovery beneﬁts to approximately one quarter of
women with ectopic pregnancies.
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